9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy

Acid-Base Homeostasis & Bicarbonate Replacement Therapy

Core Clinical Principle: Chronic metabolic acidosis in kidney disease is not merely an asymptomatic biochemical disturbance on a monthly laboratory panel; it is a potent, catabolic toxin. Uncorrected metabolic acidosis accelerates muscle protein wasting via the ubiquitin-proteasome system, dissolves bone mineral matrix, promotes vascular calcification, and accelerates the loss of residual kidney function. Correcting metabolic acidosis is an important part of renal nutrition care; KDOQI 2020 considers a serum bicarbonate of 24–26 mmol/L reasonable.

Under normal physiological conditions, endogenous metabolism of a standard Western diet produces approximately 1.0 mEq of non-volatile acid per kilogram of body weight daily (~50 to 70 mEq/day of hydrogen ions, $H^+$). This acid load is generated primarily from the oxidation of sulfur-containing amino acids (methionine and cysteine) yielding sulfuric acid ($\text{H}_2\text{SO}_4$), phosphoproteins yielding phosphoric acid ($\text{H}_3\text{PO}_4$), and incomplete metabolism of carbohydrates and fats yielding organic acids. To maintain systemic arterial blood pH within the narrow window of 7.35 to 7.45, the kidneys must perform two linked transport functions:

1. Bicarbonate Reclamation: The proximal convoluted tubule (PCT) reabsorbs virtually all filtered bicarbonate (~4,500 mEq/day) via apical NHE3 ($\text{Na}^+/\text{H}^+$ exchanger) and basolateral NBCe1 ($\text{Na}^+/3\text{HCO}_3^-$ cotransporter).
2. Net Acid Excretion (NAE): The collecting duct excretes the daily 50 to 70 mEq non-volatile acid load by generating new bicarbonate, accomplished via urinary ammonium excretion ($\text{NH}_4^+$) (~40 mEq/day) and titratable acid excretion (principally dihydrogen phosphate, $\text{H}_2\text{PO}_4^-$) (~20–30 mEq/day):

$\text{Net Acid Excretion (NAE)} = [\text{U}_{\text{NH}_4^+} \times V] + [\text{U}_{\text{Titratable Acid}} \times V] - [\text{U}_{\text{HCO}_3^-} \times V]$

---

1. Pathophysiology & Diagnostic Thresholds in CKD

As functional nephron mass declines below an eGFR of 30 to 45 mL/min/1.73m² (CKD Stages G3b–G5), total renal ammoniagenesis falls dramatically. Although surviving nephrons hyper-synthesize ammonium on a single-nephron basis, the absolute quantity of total urinary acid excretion becomes insufficient to balance endogenous production. Retention of hydrogen ions leads to progressive depletion of systemic bicarbonate buffers.

┌────────────────────────────────────────────────────────────────────────┐
│                     Diagnostic Thresholds for Acidosis                 │
├────────────────────────────────────────────────────────────────────────┤
│  Normal Serum Total CO2 / Bicarbonate:  22 – 29 mEq/L                  │
│  KDOQI 2020 target (OPINION):           24 – 26 mmol/L                 │
│  Low bicarbonate (common definition):   < 22 mEq/L                     │
│  KDIGO 2024: consider drug therapy at   < 18 mmol/L (example value)    │
│  Severe / Decompensated Acidosis:       < 18 mEq/L (Rapid catabolism)  │
└────────────────────────────────────────────────────────────────────────┘

The Anion Gap Evolution in Progressive Renal Disease

• Early to Moderate CKD (eGFR 20–45 mL/min/1.73m²): Typically manifests as a normal anion gap (hyperchloremic) metabolic acidosis. The inability to excrete ammonium is accompanied by compensatory tubular reabsorption of chloride ($\text{Cl}^-$) to maintain electroneutrality.
• Advanced CKD and ESRD (eGFR < 15–20 mL/min/1.73m²): Transforms into a high anion gap metabolic acidosis. Glomerular filtration failure prevents the clearance of unmeasured organic and inorganic acid anions, including sulfates, phosphates, urates, and hippurates:

$\text{Serum Anion Gap} = [\text{Na}^+] - ([\text{Cl}^-] + [\text{HCO}_3^-]) \quad (\text{Normal: } 8 - 12\,\text{mEq/L})$

---

2. Systemic Catabolic Consequences of Chronic Acidosis

Chronic metabolic acidosis exerts profound destructive effects across multiple organ systems, making its correction a priority in renal medical nutrition therapy:

                      Systemic Toxicity of Metabolic Acidosis
  ┌─────────────────────────────────────────────────────────────────────┐
  │  1. SKELETAL MUSCLE WASTING & ACCELERATED PROTEIN-ENERGY WASTING    │
  │     • Acidemia activates ATP-dependent Ubiquitin-Proteasome System   │
  │     • Upregulates BCKAD enzyme ➔ Degrades branched-chain amino acids │
  │     • Suppresses muscle protein synthesis ➔ Severe sarcopenia       │
  ├─────────────────────────────────────────────────────────────────────┤
  │  2. ACCELERATED BONE DEMINERALIZATION & CKD-MBD                     │
  │     • Bone acts as physicochemical buffer: H+ dissolves apatite     │
  │     • Leaches calcium and phosphate into blood ➔ Calcification      │
  │     • Inhibits osteoblasts & activates osteoclasts ➔ Osteopenia     │
  ├─────────────────────────────────────────────────────────────────────┤
  │  3. ACCELERATION OF RESIDUAL KIDNEY FUNCTION DECLINE                │
  │     • Single-nephron ammoniagenesis triggers Complement activation   │
  │     • Intrarenal Endothelin-1 & Aldosterone upregulation            │
  │     • Tubulointerstitial inflammation and progressive fibrosis      │
  ├─────────────────────────────────────────────────────────────────────┤
  │  4. ENDOCRINE & METABOLIC DYSFUNCTION                               │
  │     • Blunted peripheral insulin receptor sensitivity (Insulin Res.)│
  │     • Impaired Growth Hormone / IGF-1 signaling (Pediatric stunting)│
  │     • Transcellular shift of intracellular K+ into ECF (Hyperkalemia)│
  └─────────────────────────────────────────────────────────────────────┘

The Ubiquitin-Proteasome System (UPS) & Muscle Breakdown

At the cellular level, metabolic acidosis stimulates transcription of ubiquitin and proteasome subunits via glucocorticoid-dependent pathways. Simultaneously, acidosis upregulates branched-chain $\alpha$-ketoacid dehydrogenase (BCKAD), the rate-limiting enzyme in the oxidation of essential branched-chain amino acids (leucine, isoleucine, and valine). This double-hit induces massive myofibrillar proteolysis, breaking down actin and myosin into circulating nitrogenous wastes, worsening uremic symptoms, and driving Protein-Energy Wasting (PEW).

---

3. Oral Alkali Replacement Pharmacotherapy

The guidelines differ. KDOQI 2020 recommends reducing net acid production with bicarbonate or citrate supplements in CKD 3–5D (statement 6.1.2, grade 1C) and considers it reasonable to keep serum bicarbonate at 24–26 mmol/L (6.1.3, OPINION). KDIGO 2024 suggests considering drug treatment to prevent acidosis with clinical consequences, for example when bicarbonate falls below about 18 mmol/L, without raising it above the upper limit of normal or harming BP, potassium or fluid status.

Comparison of Oral Alkali Formulations

The Deadly Citrate-Aluminum Interaction: A Hard Safety Mandate

Citrate is a powerful trivalent cation chelator. When sodium citrate (Bicitra) is co-administered with aluminum-containing compounds (such as aluminum hydroxide phosphate binders [Amphojel] or aluminum-containing antacids), citrate solubilizes the normally insoluble aluminum precipitates in the intestinal lumen, increasing gastrointestinal aluminum absorption many-fold.

This massive influx bypasses natural gastrointestinal barrier mechanisms, causing rapid systemic accumulation in brain and bone tissue, precipitating acute dialysis encephalopathy ("dialysis dementia" with acute dyspraxia, seizures, and death) and severe vitamin D-resistant osteomalacia. Sodium citrate solutions are STRICTLY CONTRAINDICATED in any patient who may be exposed to aluminum-containing compounds.

Evaluating the Sodium Load of Alkali Therapy

A common clinical concern is whether prescribing sodium bicarbonate will exacerbate hypertension and volume overload in renal patients. Clinical nephrology trials have demonstrated that sodium bicarbonate does not expand extracellular plasma volume or elevate mean arterial pressure to the same magnitude as an equimolar quantity of sodium chloride (table salt). This phenomenon (the "chloride effect") occurs because volume expansion and renal vasoconstriction require the presence of the permeant chloride anion. Nonetheless, in patients with severe congestive heart failure or anuric fluid retention, total sodium intake must be monitored, and loop diuretic doses titrated accordingly.

---

4. Dietary Alkali & Potential Renal Acid Load (PRAL)

Dietary composition directly influences net endogenous acid production. Foods can be categorized by their Potential Renal Acid Load (PRAL), calculated from their nutrient composition:

$\text{PRAL (mEq/day)} = 0.49 \times \text{Protein (g)} + 0.037 \times \text{Phosphorus (mg)} - 0.021 \times \text{Potassium (mg)} - 0.026 \times \text{Magnesium (mg)} - 0.013 \times \text{Calcium (mg)}$

(Remer and Manz formula, using daily intakes.)

• Positive PRAL Foods (Acid-Forming): Meats, poultry, fish, eggs, cheeses, and refined cereal grains generate excess hydrogen ions via sulfur amino acid catabolism and phosphate loads.
• Negative PRAL Foods (Alkali-Forming): Fruits, vegetables, and legumes contain abundant organic potassium salts (potassium citrate, malate, and tartrate). When metabolized in the liver, these organic anions consume hydrogen ions and yield endogenous bicarbonate, acting as a natural systemic buffer.

┌────────────────────────────────────────────────────────────────────────┐
│                     PRAL Profiles of Common Food Groups                │
├────────────────────────────────────────────────────────────────────────┤
│  Parmesan / Hard Cheeses:    +25 to +35 mEq / 100g  (Highly Acidic)    │
│  Beef, Pork, Poultry, Fish:  +8 to +15 mEq / 100g   (Acid-Forming)     │
│  Refined Breads & Grains:    +3 to +7 mEq / 100g    (Mildly Acidic)    │
│  Legumes & Tofu:             -1 to -3 mEq / 100g    (Mildly Basic)     │
│  Vegetables (Carrots, Beans):-3 to -8 mEq / 100g    (Base-Forming)     │
│  Leafy Greens & Spinach:     -10 to -14 mEq / 100g  (Highly Basic)     │
│  Fruits (Apples, Berries):   -2 to -6 mEq / 100g    (Base-Forming)     │
└────────────────────────────────────────────────────────────────────────┘

Implementing a Plant-Dominant Low-Protein Diet (PLADO) in stable non-dialysis CKD patients lowers the dietary acid load, blunting or reversing mild metabolic acidosis, reducing oral bicarbonate tablet burden, and attenuating intrarenal complement-driven tubulointerstitial damage.

---

5. Dialysate Bicarbonate Titration in Hemodialysis

In maintenance hemodialysis, metabolic acidosis is corrected through the diffusive transfer of bicarbonate from the dialysate bath across the semipermeable dialyzer membrane into the blood.

• Standard Dialysate Bicarbonate Prescription: Typically set between 35 and 40 mEq/L (standard baseline: 35 or 38 mEq/L).
• The Risk of Post-Dialysis Metabolic Alkalosis: A dialysate bath $> 38$ mEq/L can cause acute post-dialysis metabolic alkalosis (venous $\text{HCO}_3^- > 28\text{ to }30\text{ mEq/L}$). Severe alkalemia induces hypokalemia (driving $K^+$ into cells), acute ionized hypocalcemia (enhancing calcium binding to albumin, provoking tetany and intradialytic cramps), hypoventilation (hypercapnia), and vascular calcification. The renal team must balance pre-dialysis acidosis correction against the hazard of post-dialysis alkalemia.